Galderma is certainly the heavyweight for rosacea treatments and skincare. Rosacea sufferers will be familiar with Metrogel 1% and Oracea as well as their Cetaphil skincare range. More recently Galderma has gained approval for Mirvaso and also has CD5024/Ivermectin in development.
The reaction online by new users of Mirvaso, you would have to say, has not been good. The reports of rebound flushing, that is; worse flushing after using Mirvaso compared to before, far outweigh happy users. From those users who have posted online at the various Mirvaso threads, the trend for adverse reactions appears to be […]
Galderma today have launched an iPhone app called Mirvaso Mirror. This app is a promotional vehicle for Galderma, aiming to engage users of Mirvaso, especially those who have an iPhone. Following in the steps of Bayer HealthCare, who publish the Rosacea App and Rosacea Concierge, Galderma is hoping to generate interest in Mirvaso. If the […]
In a followup article on François Fournier, the head of Galderma USA, the Dallas Forth Worth Daily raises the topic of rebound flushing from Mirvaso. Whilst only quoting one online forum posting, the author Bradford Pearson highlights what he calls the mixed response to the newly released topical Mirvaso. Indeed it is a question that […]
A revealing interview with the Galderma USA President Francois Fournier has just been published by the Dallas Fort Worth Healthcare Daily. This publication, `D HEALTHCARE Daily’ takes a keen interest in Galderma as the company’s US headquarters are in Forth Worth, TX. In the interview Fournier gives some interesting insights into the research and development […]
Surprise news today that Mirvaso, the product formerly known as Sansrosa, CD07805/47 and Col-118 has been granted approval by the FDA. Here are some of the things we already know about Mirvaso ; The prescription gel will be 0.33% brimonidine (this means each gram of the gel contains 5mg of birmonidine tartrate, which is the […]